XT
EBS icon

XTX Topco’s Emergent Biosolutions EBS Stock Holding History

XTX Topco’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-27,237
Closed -$174K – 2726
2025
Q2 		$174K Sell
27,237
-58,575
-68% -$335K 0.01% 1752
2025
Q1 		$417K Buy
+85,812
New +$710K 0.02% 1159
2024
Q3 		– Sell
-62,764
Closed -$428K – 2207
2024
Q2 		$428K Buy
62,764
+43,028
+218% +$185K 0.04% 736
2024
Q1 		$49.9K Buy
+19,736
New +$44.5K 0.01% 1475
2023
Q4 		– Sell
-31,462
Closed -$107K – 1716
2023
Q3 		$107K Buy
31,462
+17,636
+128% +$97.8K 0.02% 1175
2023
Q2 		$102K Buy
+13,826
New +$128K 0.02% 1163
2023
Q1 		– Sell
-15,307
Closed -$181K – 1375
2022
Q4 		$181K Buy
+15,307
New +$237K 0.04% 882
2021
Q2 		– Sell
-4,840
Closed -$450K – 871
2021
Q1 		$450K Buy
+4,840
New +$496K 0.22% 126

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
OHA
Oak Hill Advisors New York $878M AUM 106.46% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

XTX Topco's EBS Position: Q3 2025 in Review

XTX Topco sold out of Emergent Biosolutions (EBS) in Q3 2025, closing a stake of 27,237 shares — an estimated $174K sold.

XTX Topco first reported a position in EBS in Q1 2021 and held it in 8 quarters. The position peaked at $450K in Q1 2021. 169 funds tracked by Wall St. Rank hold EBS as of Q3 2025.

  • XTX Topco reported no remaining Emergent Biosolutions position as of Q3 2025 after selling out during the quarter.
  • XTX Topco sold 27,237 Emergent Biosolutions shares in Q3 2025, an estimated $174K.
  • XTX Topco first reported a position in Emergent Biosolutions in Q1 2021 and held it in 8 quarters.
  • XTX Topco's Emergent Biosolutions position peaked at $450K in Q1 2021.
  • 169 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2025.

Based on XTX Topco's 13F filing for Q3 2025, filed 14 Nov 2025.